Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals Of The Week Looks At The Intersection Of Patient Empowerment, Generic Drugs And Macaroni & Cheese

Executive Summary

Over one-third of practicing physicians cave in to patient requests for a brand-name drug over a generic, but can the trend hold? Also, deals by Baxter/Xenetic, AstraZeneca/FOB, Galectin/SBH, Biogen/UCB and Actavis/Zhejiang Chiral Medicine Chemicals.

You may also be interested in...



An Antibiotic Anniversary Celebration: Deal-Making and Investment Are Active In Formerly Moribund Field

A year ago, the Pew Trust hosted a meeting on antibiotic development that emphasized the many barriers still discouraging investment in the field despite new legislation (the GAIN Act). Three coincidental announcements in early 2014 show that the development freeze in anti-infectives is beginning to thaw.

Biogen Sets Aside Cash For Business Development, Expects New Launches In 2014

The spec pharma had a strong year and will continue to rely on new product launches going forward, but hopes to bolster its pipeline with early-stage add-ons.

People Power: How The Crowd May Shape The Funding And Development Of Drugs

Companies are sprouting across the pharma value chain that harness the voices of patients and other individual stakeholders to drive the research, development, and financing of drugs. Pharma is taking tentative steps toward using these methods, but high barriers remain to their systematic integration in R&D.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS055897

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel